A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma
| ISRCTN | ISRCTN54481540 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN54481540 |
| Secondary identifying numbers | N0256159469 |
- Submission date
- 30/09/2005
- Registration date
- 30/09/2005
- Last edited
- 26/10/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Andrew K Burroughs
Scientific
Scientific
Department of Liver Medicine & Transplantation
Royal Free Hampstead NHS Trust
Pond Street
Hampstead
London
NW3 2QG
United Kingdom
Study information
| Study design | Randomised parallel-group study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma |
| Study objectives | Which is the best treatment in terms of survival of patients diagnosed with unresectable unifocal hepatocellular carcinoma (HCC) less than 3 cm in diameter treated with percutaneous ethanol injection or transarterial particle embolisation? |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Cancer: Liver |
| Intervention | Percutaneous ethanol injection or transarterial particle embolisation |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Ethanol |
| Primary outcome measure | Survival of patient after treatment of unresectable, unifocal, small (3 cm) hepatocellular carcinoma |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 31/07/2003 |
| Completion date | 31/07/2006 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 185 |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 31/07/2003 |
| Date of final enrolment | 31/07/2006 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Royal Free Hampstead NHS Trust
London
NW3 2QG
United Kingdom
NW3 2QG
United Kingdom
Sponsor information
Department of Health
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Phone | +44 (0)20 7307 2622 |
|---|---|
| dhmail@doh.gsi.org.uk | |
| Website | http://www.dh.gov.uk/Home/fs/en |
Funders
Funder type
Government
The Royal Free Hampstead NHS Trust (UK)
No information available
NHS R&D Support Funding
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
